+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07659795

Phase 2 Open-Label Study of Oral VS-7375 with or without Anti-EGFR Antibodies and Chemotherapy in Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma

Led by Verastem, Inc. · Updated on 2026-10-26

150

Participants Needed

30

Research Sites

78 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of VS-7375, alone and combined with cetuximab or panitumumab, as well as cetuximab plus mFOLFOX chemotherapy, in patients with metastatic colorectal cancer that has a KRAS G12D mutation. This phase 2 study focuses on patients who have either not received prior treatment or have progressed after previous therapies. The goal is to understand how well these treatments work and how safe they are for this specific cancer type. Participants receive one of several treatment regimens VS-7375 alone or combined with cetuximab or panitumumab for patients with second-line or later metastatic colorectal cancer, or VS-7375 combined with cetuximab and mFOLFOX chemotherapy for patients newly diagnosed or with limited prior treatment. The study involves daily oral dosing of VS-7375 and intravenous infusions of the other drugs. Treatments are assigned randomly in a 21 ratio, and participants may cross over between treatments. Throughout the study, participants attend regular visits for evaluations including tumor assessments using RECIST criteria, safety and tolerability monitoring, blood tests for drug levels and tumor markers, and quality of life questionnaires. These assessments occur over periods ranging from 6 months to 2.5 years. The study measures confirmed tumor response rates and monitors for side effects to better understand the potential of these treatments for metastatic colorectal cancer. Participation may last until study completion in late 2028.

CONDITIONS

Brief Title

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

Research Team

V

Verastem Call Center

B

Bina Tejura, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here